Edition:
United Kingdom

Sarepta Therapeutics Inc (SRPT.OQ)

SRPT.OQ on NASDAQ Stock Exchange Global Select Market

121.32USD
17 Jan 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$121.32
Open
$118.35
Day's High
$124.09
Day's Low
$117.49
Volume
258,604
Avg. Vol
349,461
52-wk High
$176.44
52-wk Low
$50.68

Latest Key Developments (Source: Significant Developments)

Sarepta Therapeutics Says Q4 Rev Was About $84.4 Mln
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Sarepta Therapeutics Inc ::COMPANY GENERATED APPROXIMATELY $84.4 MILLION IN REVENUE (UNAUDITED) IN THE FOURTH QUARTER ENDED DECEMBER 31, 2018.CASH POSITION OF $1.1 BILLION AS OF DECEMBER 31, 2018.Q4 REVENUE VIEW $85.8 MILLION -- REFINITIV IBES DATA.  Full Article

Sarepta Therapeutics Announces Pricing Of $500 Mln Public Offering
Friday, 9 Nov 2018 

Nov 8 (Reuters) - Sarepta Therapeutics Inc ::SAREPTA THERAPEUTICS ANNOUNCES PRICING OF $500,000,000 PUBLIC OFFERING OF COMMON STOCK.SAREPTA THERAPEUTICS INC- PRICED UNDERWRITTEN PUBLIC OFFERING OF AGGREGATE OF 3.8 MILLION SHARES OF ITS COMMON STOCK AT $131 PER SHARE.  Full Article

Sarepta Therapeutics Announces Q3 2018 Financial Results And Recent Corporate Developments
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Sarepta Therapeutics Inc ::SAREPTA THERAPEUTICS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS.Q3 NON-GAAP LOSS PER SHARE $0.56.Q3 REVENUE $78.5 MILLION VERSUS I/B/E/S VIEW $79.3 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.81 -- THOMSON REUTERS I/B/E/S.  Full Article

Sarepta Announces Clinical Hold Lifted For Its Duchenne Muscular Dystrophy Micro-Dystrophin Gene Therapy Program
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Sarepta Therapeutics Inc ::SAREPTA ANNOUNCES CLINICAL HOLD LIFTED FOR ITS DUCHENNE MUSCULAR DYSTROPHY MICRO-DYSTROPHIN GENE THERAPY PROGRAM.SAREPTA THERAPEUTICS - IN RESPONSE, ACTION PLAN DEVELOPED, SUBMITTED TO FDA, INCLUDING AUDIT OF PLASMID SUPPLIER.SAREPTA THERAPEUTICS - PLAN SUBMITTED TO FDA, INCLUDES COMMITMENT TO USE GMP-S PLASMID FOR ALL FUTURE PRODUCTION LOTS.SAREPTA THERAPEUTICS INC - CO HOPES TO REGISTER FOR TRIAL FOR MICRO-DYSTROPHIN PROGRAM & COMMENCING TRIAL BY YEAR-END 2018.  Full Article

Sarepta Receives Negative CHMP Re-Examination Opinion For Eteplirsen
Friday, 21 Sep 2018 

Sept 21 (Reuters) - Sarepta Therapeutics Inc ::SAREPTA RECEIVES NEGATIVE CHMP RE-EXAMINATION OPINION FOR ETEPLIRSEN.SAREPTA THERAPEUTICS INC - WILL SEEK FURTHER SCIENTIFIC ADVICE FROM EUROPEAN MEDICINES AGENCY ON A POSSIBLE PATH TO BRING ETEPLIRSEN TO PATIENTS IN EUROPE.SAREPTA -WILL SEEK FURTHER SCIENTIFIC ADVICE FROM EUROPEAN MEDICINES AGENCY ON A POSSIBLE PATH TO BRING ETEPLIRSEN TO PATIENTS IN EUROPE.SAREPTA THERAPEUTICS INC - EXPECTS EUROPEAN COMMISSION (EC) TO ADOPT CHMP OPINION BY YEAR-END 2018.  Full Article

Sarepta Therapeutics Q2 Non-GAAP Loss Per Share $0.43
Wednesday, 8 Aug 2018 

Sarepta Therapeutics Inc ::SAREPTA THERAPEUTICS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS.Q2 NON-GAAP LOSS PER SHARE $0.43.Q2 REVENUE $73.5 MILLION VERSUS I/B/E/S VIEW $71.6 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.89 -- THOMSON REUTERS I/B/E/S.ON A NON-GAAP BASIS, NET LOSS FOR Q2 WAS $0.43 PER SHARE.QTRLY GAAP NET LOSS PER SHARE $1.67.  Full Article

Sarepta Receives Negative CHMP Opinion For Exondys
Friday, 1 Jun 2018 

June 1 (Reuters) - Sarepta Therapeutics Inc ::AS ANTICIPATED, SAREPTA RECEIVES NEGATIVE CHMP OPINION FOR EXONDYS® (ETEPLIRSEN) TO TREAT PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY IN EUROPE.SAREPTA THERAPEUTICS INC - SAREPTA WILL SEEK RE-EXAMINATION OF OPINION AND REQUEST THAT A SCIENTIFIC ADVISORY GROUP (SAG) BE CONVENED.SAREPTA THERAPEUTICS INC - WILL SEEK RE-EXAMINATION OF OPINION AND REQUEST THAT A SCIENTIFIC ADVISORY GROUP (SAG) BE CONVENED.SAREPTA THERAPEUTICS INC - RE-EXAMINATION PROCESS IS EXPECTED TO BE COMPLETED BY YEAR-END 2018.SAREPTA THERAPEUTICS INC - WILL ALSO REQUEST A SCIENTIFIC ADVISORY GROUP ON DMD BE CALLED.SAREPTA THERAPEUTICS INC - WILL REQUEST A RE-EXAMINATION OF OPINION, WHICH WILL RESULT IN ASSIGNMENT OF A NEW RAPPORTEUR AND CO-RAPPORTEUR.  Full Article

Sarepta Therapeutics Provides FY 2018 Rev Forecast For Exondys 51
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Sarepta Therapeutics Inc ::SAREPTA THERAPEUTICS PRE-ANNOUNCES FOURTH QUARTER 2017 REVENUE AND PROVIDES FULL-YEAR 2018 REVENUE GUIDANCE FOR EXONDYS 51® (ETEPLIRSEN), REPRESENTING APPROXIMATELY 100 PERCENT YEAR-OVER-YEAR GROWTH.Q4 REVENUE $57.3 MILLION VERSUS I/B/E/S VIEW $55.8 MILLION.SEES FY 2018 REVENUE $295 MILLION TO $305 MILLION.SAYS FULL-YEAR 2018 EXONDYS 51 REVENUE GUIDANCE OF $295 - $305 MILLION.SAYS ‍FULL-YEAR 2017 EXONDYS 51 UNAUDITED REVENUE OF $154.6 MILLION​.  Full Article

Capital Ventures International Reports 5.4 Pct Passive Stake In Sarepta Therapeutics
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Sarepta Therapeutics Inc ::CAPITAL VENTURES INTERNATIONAL REPORTS A 5.4 PERCENT PASSIVE STAKE IN SAREPTA THERAPEUTICS INC AS OF DECEMBER 11, 2017 - SEC FILING.  Full Article

Sarepta Therapeutics prices $475 million of convertible senior notes due 2024
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Sarepta Therapeutics Inc :Sarepta Therapeutics prices $475 million of convertible senior notes due 2024.Sarepta Therapeutics-‍priced $475 million aggregate principal amount of convertible senior unsecured notes that will mature on November 15, 2024​.Sarepta Therapeutics - ‍notes will bear cash interest at a rate of 1.50%, payable on May 15 and November 15 of each year, beginning on May 15, 2018​.  Full Article